Editor’s Pick: PRINT trial examines small cell/NE morphing … not to mention EXERCISE beats fatigue! (rd)
Topics Discussed
DeNovo Metastatic man enters trial for HPN424; yet more monotherapy bicalutamide – after 17 yrs of no treatment!; FMI finds ROS1 – what next; introducing palliative care; bone cancer pain or arthritis; PRINT trial looks to thwart PCa cells morphing to small cell/NE; clinical trials still shut down nationally; to radiate or not with 5 lesions?; Procrit?; another denovo Mx man asks should he do chemo?; EXERCISE WORKS to relieve fatigue from salvage RT!!!; remedies for hot sweats.
Chat Log
Jake (to Everyone): 5:19 PM: HPN424
Jake (to Everyone): 5:20 PM: https://www.biospace.com/article/releases/harpoon-therapeutics-announces-preliminary-safety-and-pharmacology-data-from-its-hpn424-phase-1-trial-in-prostate-cancer/
Rich Jackson (to Organizer(s) Only): 6:22 PM: About rhPSMA rhPSMA-7.3 (18F) consists of a radiohybrid Prostate-Specific Membrane Antigen (PSMA)-targeted receptor ligand which attaches to and is internalized by prostate cancer cells, and is labeled with the 18F radioisotope for PET imaging. Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
Dennis Correia (to Everyone): 6:32 PM: nct#02903160 (PRINT Trial)
Larry Fish (to Everyone): 7:05 PM: MMR mismatch repair deficiency
AnCan – Rick (to Everyone): 7:15 PM: https://www.urotoday.com/video-lectures/mcrpc-treatment/video/mediaitem/843-embedded-media2017-10-09-16-50-00.html?utm_source=newsletter_4869&utm_medium=email&utm_campaign=navigating-the-course-of-treatment-new-findings-meet-old-habits-findings-from-latitude